Selexis and OSE Immunotherapeutics to support OSE-127 (Effi-7) development

Swiss-based Selexis has signed a commercial licence agreement to provide French biotechnology firm OSE Immunotherapeutics with access to high-performance research cell banks (RCBs) from its SUREtechnology Platform.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news